Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Validation of Thiosemicarbazone Compounds as P-Glycoprotein Inhibitors in Human Primary Brain-Blood Barrier and Glioblastoma Stem Cells.

Salaroglio IC, Abate C, Rolando B, Battaglia L, Gazzano E, Colombino E, Costamagna C, Annovazzi L, Mellai M, Berardi F, Capucchio MT, Schiffer D, Riganti C.

Mol Pharm. 2019 Aug 5;16(8):3361-3373. doi: 10.1021/acs.molpharmaceut.9b00018. Epub 2019 Jul 2.

PMID:
31265310
2.

SEL1L plays a major role in human malignant gliomas.

Mellai M, Annovazzi L, Boldorini R, Bertero L, Cassoni P, De Blasio P, Biunno I, Schiffer D.

J Pathol Clin Res. 2019 May 20. doi: 10.1002/cjp2.134. [Epub ahead of print]

3.

Glioblastoma: Microenvironment and Niche Concept.

Schiffer D, Annovazzi L, Casalone C, Corona C, Mellai M.

Cancers (Basel). 2018 Dec 20;11(1). pii: E5. doi: 10.3390/cancers11010005. Review.

4.

Carbonic Anhydrase XII Inhibitors Overcome P-Glycoprotein-Mediated Resistance to Temozolomide in Glioblastoma.

Salaroglio IC, Mujumdar P, Annovazzi L, Kopecka J, Mellai M, Schiffer D, Poulsen SA, Riganti C.

Mol Cancer Ther. 2018 Dec;17(12):2598-2609. doi: 10.1158/1535-7163.MCT-18-0533. Epub 2018 Sep 25.

PMID:
30254183
5.

Correction: SEL1L SNP rs12435998, a predictor of glioblastoma survival and response to radio-chemotherapy.

Mellai M, Cattaneo M, Storaci AM, Annovazzi L, Cassoni P, Melcarne A, De Blasio P, Schiffer D, Biunno I.

Oncotarget. 2018 Aug 24;9(66):32731. doi: 10.18632/oncotarget.26066. eCollection 2018 Aug 24.

6.

The Significance of Chondroitin Sulfate Proteoglycan 4 (CSPG4) in Human Gliomas.

Schiffer D, Mellai M, Boldorini R, Bisogno I, Grifoni S, Corona C, Bertero L, Cassoni P, Casalone C, Annovazzi L.

Int J Mol Sci. 2018 Sep 12;19(9). pii: E2724. doi: 10.3390/ijms19092724. Review.

7.

Glioblastoma niches: from the concept to the phenotypical reality.

Schiffer D, Mellai M, Bovio E, Bisogno I, Casalone C, Annovazzi L.

Neurol Sci. 2018 Jul;39(7):1161-1168. doi: 10.1007/s10072-018-3408-0. Epub 2018 May 8. Review.

PMID:
29736738
8.

Microglia immunophenotyping in gliomas.

Annovazzi L, Mellai M, Bovio E, Mazzetti S, Pollo B, Schiffer D.

Oncol Lett. 2018 Jan;15(1):998-1006. doi: 10.3892/ol.2017.7386. Epub 2017 Nov 9.

9.

Solid Lipid Nanoparticles Carrying Temozolomide for Melanoma Treatment. Preliminary In Vitro and In Vivo Studies.

Clemente N, Ferrara B, Gigliotti CL, Boggio E, Capucchio MT, Biasibetti E, Schiffer D, Mellai M, Annovazzi L, Cangemi L, Muntoni E, Miglio G, Dianzani U, Battaglia L, Dianzani C.

Int J Mol Sci. 2018 Jan 24;19(2). pii: E255. doi: 10.3390/ijms19020255.

10.

Comparison among conventional and advanced MRI, 18F-FDG PET/CT, phenotype and genotype in glioblastoma.

Valentini MC, Mellai M, Annovazzi L, Melcarne A, Denysenko T, Cassoni P, Casalone C, Maurella C, Grifoni S, Fania P, Cistaro A, Schiffer D.

Oncotarget. 2017 Oct 4;8(53):91636-91653. doi: 10.18632/oncotarget.21482. eCollection 2017 Oct 31.

11.

The neuropathological basis to the functional role of microglia/macrophages in gliomas.

Schiffer D, Mellai M, Bovio E, Annovazzi L.

Neurol Sci. 2017 Sep;38(9):1571-1577. doi: 10.1007/s10072-017-3002-x. Epub 2017 Jun 7. Review.

PMID:
28593528
12.

Chemotherapeutic Drugs: DNA Damage and Repair in Glioblastoma.

Annovazzi L, Mellai M, Schiffer D.

Cancers (Basel). 2017 May 26;9(6). pii: E57. doi: 10.3390/cancers9060057. Review.

13.

Comparison of Allogeneic and Syngeneic Rat Glioma Models by Using MRI and Histopathologic Evaluation.

Biasibetti E, Valazza A, Capucchio MT, Annovazzi L, Battaglia L, Chirio D, Gallarate M, Mellai M, Muntoni E, Peira E, Riganti C, Schiffer D, Panciani P, Lanotte M.

Comp Med. 2017 Mar 1;67(2):147-156.

14.

Solid lipid nanoparticles by coacervation loaded with a methotrexate prodrug: preliminary study for glioma treatment.

Battaglia L, Muntoni E, Chirio D, Peira E, Annovazzi L, Schiffer D, Mellai M, Riganti C, Salaroglio IC, Lanotte M, Panciani P, Capucchio MT, Valazza A, Biasibetti E, Gallarate M.

Nanomedicine (Lond). 2017 Mar;12(6):639-656. doi: 10.2217/nnm-2016-0380. Epub 2017 Feb 10.

PMID:
28186465
15.

A comprehensive view of tumor stem cells and their regulation by the microenvironment in glioblastoma.

Schiffer D, Annovazzi L, Mellai M.

Neurol Sci. 2017 Mar;38(3):527-529. doi: 10.1007/s10072-016-2768-6. Epub 2016 Nov 16. No abstract available.

PMID:
27853910
16.

Diagnostic revision of 206 adult gliomas (including 40 oligoastrocytomas) based on ATRX, IDH1/2 and 1p/19q status.

Mellai M, Annovazzi L, Senetta R, Dell'Aglio C, Mazzucco M, Cassoni P, Schiffer D.

J Neurooncol. 2017 Jan;131(2):213-222. doi: 10.1007/s11060-016-2296-5. Epub 2016 Oct 28.

PMID:
27796734
17.

WNT/β-catenin Signaling Pathway and Downstream Modulators in Low- and High-grade Glioma.

Denysenko T, Annovazzi L, Cassoni P, Melcarne A, Mellai M, Schiffer D.

Cancer Genomics Proteomics. 2016 Jan-Feb;13(1):31-45.

18.

The Microenvironment in Gliomas: Phenotypic Expressions.

Schiffer D, Annovazzi L, Mazzucco M, Mellai M.

Cancers (Basel). 2015 Dec 3;7(4):2352-9. doi: 10.3390/cancers7040896.

19.

SEL1L SNP rs12435998, a predictor of glioblastoma survival and response to radio-chemotherapy.

Mellai M, Cattaneo M, Storaci AM, Annovazzi L, Cassoni P, Melcarne A, De Blasio P, Schiffer D, Biunno I.

Oncotarget. 2015 May 20;6(14):12452-67. Erratum in: Oncotarget. 2018 Aug 24;9(66):32731.

20.

The DNA damage/repair cascade in glioblastoma cell lines after chemotherapeutic agent treatment.

Annovazzi L, Caldera V, Mellai M, Riganti C, Battaglia L, Chirio D, Melcarne A, Schiffer D.

Int J Oncol. 2015;46(6):2299-308. doi: 10.3892/ijo.2015.2963. Epub 2015 Apr 16.

21.

Astroblastoma: beside being a tumor entity, an occasional phenotype of astrocytic gliomas?

Mellai M, Piazzi A, Casalone C, Grifoni S, Melcarne A, Annovazzi L, Cassoni P, Denysenko T, Valentini MC, Cistaro A, Schiffer D.

Onco Targets Ther. 2015 Feb 19;8:451-60. doi: 10.2147/OTT.S71384. eCollection 2015.

22.

Positive-charged solid lipid nanoparticles as paclitaxel drug delivery system in glioblastoma treatment.

Chirio D, Gallarate M, Peira E, Battaglia L, Muntoni E, Riganti C, Biasibetti E, Capucchio MT, Valazza A, Panciani P, Lanotte M, Annovazzi L, Caldera V, Mellai M, Filice G, Corona S, Schiffer D.

Eur J Pharm Biopharm. 2014 Nov;88(3):746-58.

23.

Stem cell niches in glioblastoma: a neuropathological view.

Schiffer D, Mellai M, Annovazzi L, Caldera V, Piazzi A, Denysenko T, Melcarne A.

Biomed Res Int. 2014;2014:725921. doi: 10.1155/2014/725921. Epub 2014 Apr 15.

24.

Solid lipid nanoparticles for potential doxorubicin delivery in glioblastoma treatment: preliminary in vitro studies.

Battaglia L, Gallarate M, Peira E, Chirio D, Muntoni E, Biasibetti E, Capucchio MT, Valazza A, Panciani PP, Lanotte M, Schiffer D, Annovazzi L, Caldera V, Mellai M, Riganti C.

J Pharm Sci. 2014 Jul;103(7):2157-2165. doi: 10.1002/jps.24002. Epub 2014 May 13.

25.

Promoter hypermethylation of the EMP3 gene in a series of 229 human gliomas.

Mellai M, Piazzi A, Caldera V, Annovazzi L, Monzeglio O, Senetta R, Cassoni P, Schiffer D.

Biomed Res Int. 2013;2013:756302. doi: 10.1155/2013/756302. Epub 2013 Sep 3.

26.

Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/glycogen synthase-3 kinase/β-catenin pathway.

Riganti C, Salaroglio IC, Caldera V, Campia I, Kopecka J, Mellai M, Annovazzi L, Bosia A, Ghigo D, Schiffer D.

Neuro Oncol. 2013 Nov;15(11):1502-17. doi: 10.1093/neuonc/not104. Epub 2013 Jul 28.

27.

Temozolomide down-regulates P-glycoprotein in human blood-brain barrier cells by disrupting Wnt3 signaling.

Riganti C, Salaroglio IC, Pinzòn-Daza ML, Caldera V, Campia I, Kopecka J, Mellai M, Annovazzi L, Couraud PO, Bosia A, Ghigo D, Schiffer D.

Cell Mol Life Sci. 2014 Feb;71(3):499-516. doi: 10.1007/s00018-013-1397-y. Epub 2013 Jun 15.

28.

MGMT hypermethylation and MDR system in glioblastoma cancer stem cells.

Caldera V, Mellai M, Annovazzi L, Monzeglio O, Piazzi A, Schiffer D.

Cancer Genomics Proteomics. 2012 Jul-Aug;9(4):171-8.

PMID:
22798502
29.

MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors.

Mellai M, Monzeglio O, Piazzi A, Caldera V, Annovazzi L, Cassoni P, Valente G, Cordera S, Mocellini C, Schiffer D.

J Neurooncol. 2012 May;107(3):617-31. doi: 10.1007/s11060-011-0787-y.

PMID:
22287028
30.

Antigenic and Genotypic Similarity between Primary Glioblastomas and Their Derived Neurospheres.

Caldera V, Mellai M, Annovazzi L, Piazzi A, Lanotte M, Cassoni P, Schiffer D.

J Oncol. 2011;2011:314962. doi: 10.1155/2011/314962. Epub 2011 Aug 18.

31.

SOX2 expression and amplification in gliomas and glioma cell lines.

Annovazzi L, Mellai M, Caldera V, Valente G, Schiffer D.

Cancer Genomics Proteomics. 2011 May-Jun;8(3):139-47.

PMID:
21518820
32.

On the origin and growth of gliomas.

Schiffer D, Annovazzi L, Caldera V, Mellai M.

Anticancer Res. 2010 Jun;30(6):1977-98. Review.

PMID:
20651342
33.

mTOR, S6 and AKT expression in relation to proliferation and apoptosis/autophagy in glioma.

Annovazzi L, Mellai M, Caldera V, Valente G, Tessitore L, Schiffer D.

Anticancer Res. 2009 Aug;29(8):3087-94.

34.

MGMT promoter hypermethylation in a series of 104 glioblastomas.

Mellai M, Caldera V, Annovazzi L, Chiò A, Lanotte M, Cassoni P, Finocchiaro G, Schiffer D.

Cancer Genomics Proteomics. 2009 Jul-Aug;6(4):219-27.

35.

An engineering, multiscale constitutive model for fiber-forming collagen in tension.

Annovazzi L, Genna F.

J Biomed Mater Res A. 2010 Jan;92(1):254-66. doi: 10.1002/jbm.a.32352.

PMID:
19180522
36.

Survivin expression in glioblastomas correlates with proliferation, but not with apoptosis.

Mellai M, Caldera V, Patrucco A, Annovazzi L, Schiffer D.

Anticancer Res. 2008 Jan-Feb;28(1A):109-18.

37.

Stat3 expression and its correlation with proliferation and apoptosis/autophagy in gliomas.

Caldera V, Mellai M, Annovazzi L, Valente G, Tessitore L, Schiffer D.

J Oncol. 2008;2008:219241. doi: 10.1155/2008/219241. Epub 2009 Apr 27.

38.

Progress in the methodological strategies for the detection in real samples of desmosine and isodesmosine, two biological markers of elastin degradation.

Viglio S, Annovazzi L, Luisetti M, Stolk J, Casado B, Iadarola P.

J Sep Sci. 2007 Feb;30(2):202-13. Review.

PMID:
17390614
39.

Association between markers of emphysema and more severe chronic obstructive pulmonary disease.

Boschetto P, Quintavalle S, Zeni E, Leprotti S, Potena A, Ballerin L, Papi A, Palladini G, Luisetti M, Annovazzi L, Iadarola P, De Rosa E, Fabbri LM, Mapp CE.

Thorax. 2006 Dec;61(12):1037-42. Epub 2006 Jun 12.

40.

The role of emerging techniques in the investigation of prolidase deficiency: from diagnosis to the development of a possible therapeutical approach.

Viglio S, Annovazzi L, Conti B, Genta I, Perugini P, Zanone C, Casado B, Cetta G, Iadarola P.

J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Feb 17;832(1):1-8. Epub 2006 Jan 24. Review.

PMID:
16434239
41.

Short-term variability of biomarkers of proteinase activity in patients with emphysema associated with type Z alpha-1-antitrypsin deficiency.

Stolk J, Veldhuisen B, Annovazzi L, Zanone C, Versteeg EM, van Kuppevelt TH, Berden JH, Nieuwenhuizen W, Iadarola P, Luisetti M.

Respir Res. 2005 May 31;6:47. Erratum in: Respir Res. 2006;7(1):20. Berden, Jo H M [added].

42.

Micellar electrokinetic chromatographic and capillary zone electrophoretic methods for screening urinary biomarkers of human disorders: a critical review of the state-of-the-art.

Iadarola P, Cetta G, Luisetti M, Annovazzi L, Casado B, Baraniuk J, Zanone C, Viglio S.

Electrophoresis. 2005 Feb;26(4-5):752-66. Review.

PMID:
15669008
43.

Urinary electrophoretic profiles from chronic fatigue syndrome and chronic fatigue syndrome/fibromyalgia patients: a pilot study for achieving their normalization.

Casado B, Zanone C, Annovazzi L, Iadarola P, Whalen G, Baraniuk JN.

J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Jan 5;814(1):43-51.

PMID:
15607706
44.

Pyrimidine 5'-nucleotidase activities detected in real samples by means of micellar electrokinetic chromatography.

Zanone C, Chiarelli LR, Valentini G, Perani E, Annovazzi L, Viglio S, Iadarola P.

Electrophoresis. 2004 Oct;25(18-19):3270-6.

PMID:
15472954
45.

High-performance liquid chromatography and capillary electrophoresis: methodological challenges for the determination of biologically relevant low-aliphatic aldehydes in human saliva.

Annovazzi L, Cattaneo V, Viglio S, Perani E, Zanone C, Rota C, Pecora F, Cetta G, Silvestri M, Iadarola P.

Electrophoresis. 2004 May;25(9):1255-63.

PMID:
15174046
46.

Capillary electrophoresis with laser-induced fluorescence detection as a novel sensitive approach for the analysis of desmosines in real samples.

Annovazzi L, Viglio S, Perani E, Luisetti M, Baraniuk J, Casado B, Cetta G, Iadarola P.

Electrophoresis. 2004 Feb;25(4-5):683-91.

PMID:
14981697
47.

High levels of desmosines in urine and plasma of patients with pseudoxanthoma elasticum.

Annovazzi L, Viglio S, Gheduzzi D, Pasquali-Ronchetti I, Zanone C, Cetta G, Iadarola P.

Eur J Clin Invest. 2004 Feb;34(2):156-64.

PMID:
14764080
48.

Therapeutic apheresis exchange in two patients with prolidase deficiency.

Lupi A, Casado B, Soli M, Bertazzoni M, Annovazzi L, Viglio S, Cetta G, Iadarola P.

Br J Dermatol. 2002 Dec;147(6):1237-40.

PMID:
12452876
49.

Collagenase production in an antarctic strain of Arthrobotrys tortor Jarowaja.

Tosi S, Annovazzi L, Tosi I, Iadarola P, Caretta G.

Mycopathologia. 2002;153(3):157-62.

PMID:
11998879
50.

[Some results of chemotherapy of cancer].

CERESA C, ANNOVAZZI L, DE BLASIIS M.

G Ital Chemioter. 1954 Jan-Mar;1(1):148-53. Italian. No abstract available.

PMID:
13191610

Supplemental Content

Loading ...
Support Center